After over a decade long dry spell, The Food and Drug Administration (FDA) has approved two new therapies, boceprevir and telaprevir, for the treatment of Hepatitis C. Both therapies signal a breakthrough in the treatment of Hepatitis C with the possibility of boosting cure rates to as high as 70 percent when used in conjunction with existing treatment medications.
Mayo Clinic physicians, Hugo Vargas, M.D., Chair of Transplant Medicine in Phoenix, AZ and Denise Harnois, D.O., hepatologist in Jacksonville, FL offer their perspectives on these new therapies.
What is Hepatitis C?
Dr. Harnois provides an overview of this bloodborne virus which affects more than four million people in the United States according to the National Institutes of Health.
How is Hepatitis C spread?
Dr. Vargas explains the most common ways that people can acquire Hepatitis C:
What is the current treatment for hepatitis C?
There is no vaccine for hepatitis C. Dr. Harnois discusses the current treatment therapies and reviews the cure rate:
What new therapies are on the horizon?
Boceprevir and telaprevir both block a key enzyme that prevents the hepatitis C virus from replicating.
Dr. Vargas shares how these two new medications would benefit those patients with Hepatitis C: